摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3aR,6aR)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl acetate | 1055283-74-3

中文名称
——
中文别名
——
英文名称
(3aR,6aR)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl acetate
英文别名
——
(3aR,6aR)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl acetate化学式
CAS
1055283-74-3
化学式
C9H14O5
mdl
——
分子量
202.207
InChiKey
GFCSYKYRSODEGC-GCJDJSOWSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.43
  • 重原子数:
    14.0
  • 可旋转键数:
    1.0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    53.99
  • 氢给体数:
    0.0
  • 氢受体数:
    5.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (3aR,6aR)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl acetate2,6-二氯嘌呤硫酸氢铵六甲基二硅氮烷三氟甲磺酸三甲基硅酯 作用下, 以 1,2-二氯乙烷 为溶剂, 以69%的产率得到2,6-dichloro-9-((3aR,4R,6aR)-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-yl)-9H-purine
    参考文献:
    名称:
    A3腺苷受体结合亲和力与截短腺苷衍生物抗肾间质纤维化活性的相关性研究
    摘要:
    截短的 4'-硫代核苷 1-4 和 4'-氧代核苷 5-8 作为有效和选择性的 A3AR 拮抗剂分别由 d-甘露糖和 d-赤藓酸γ-内酯合成。评估了这些核苷在 TGF-β1 处理的小鼠近端肾小管 (mProx) 细胞中的抗纤维化肾脏保护活性。它们对 A3AR 的拮抗活性与它们对 mProx 细胞中 TGF-β1 诱导的胶原 I 上调的抑制活性成正比。该结果表明 A3AR 拮抗剂的结合亲和力与其抗纤维化活性密切相关。因此,A3AR 拮抗剂可能是治疗慢性肾病的新型候选药物。
    DOI:
    10.1007/s12272-018-1079-2
  • 作为产物:
    参考文献:
    名称:
    截短的 2,8-二取代腺苷衍生物作为双重 A2A/A3 腺苷受体拮抗剂的构效关系及其癌症免疫治疗活性
    摘要:
    基于hA 2A AR结构,5'-截短腺苷类似物中的疏水性C8-杂芳环紧密占据亚袋,将hA 2A AR激动剂转化为拮抗剂,同时保持对hA 3 AR的亲和力。使用 Pd 催化剂,分别从d-甘露糖和d-赤酮-1,4-内酯合成 2,8-二取代-N 6 -取代的 4'-硫代核苷或 4'-氧代的最终化合物。受控的区域选择性交叉偶联反应。所有测试的化合物均完全拮抗 hA 2A AR,包括5d时具有最高亲和力 ( K i,A 2A = 7.7 ± 0.5 nM)。 hA 2A AR– 5d X 射线结构表明,C8 杂芳环可阻止受体激活相关的构象变化。然而,C8取代的化合物仍然拮抗hA 3 AR。结构 SAR 特征和对接研究支持 A 2A AR 和 A 3 AR 的不同结合模式,阐明了受体激活和选择性的药效团。证明了良好的药代动力学,其中5d表现出高口服吸收、中等半衰期和生物利用度。而且, 5d后抗PD-L
    DOI:
    10.1021/acs.jmedchem.3c00806
点击查看最新优质反应信息

文献信息

  • Structure–Activity Relationships of Truncated C2- or C8-Substituted Adenosine Derivatives as Dual Acting A<sub>2A</sub> and A<sub>3</sub> Adenosine Receptor Ligands
    作者:Xiyan Hou、Mahesh S. Majik、Kyunglim Kim、Yuna Pyee、Yoonji Lee、Varughese Alexander、Hwa-Jin Chung、Hyuk Woo Lee、Girish Chandra、Jin Hee Lee、Seul-gi Park、Won Jun Choi、Hea Ok Kim、Khai Phan、Zhan-Guo Gao、Kenneth A. Jacobson、Sun Choi、Sang Kook Lee、Lak Shin Jeong
    DOI:10.1021/jm201229j
    日期:2012.1.12
    Truncated N-6-substituted-4'-oxo- and 4'-thioadenosine derivatives with C2 or C8 substitution were studied as dual acting A(2A) and A(3) adenosine receptor (AR) ligands. The lithiation-mediated stannyl transfer and palladium-catalyzed cross-coupling reactions were utilized for functionalization of the C2 position of 6-chloropurine nucleosides. An unsubstituted 6-amino group and a hydrophobic C2 substituent were required for high affinity at the hA(2A)AR, but hydrophobic C8 substitution abolished binding at the hA(2A)AR. However, most of synthesized compounds displayed medium to high binding affinity at the hA(3)AR, regardless of C2 or C8 substitution, and low efficacy in a functional cAMP assay. Several compounds tended to be full hA(2A)AR agonists. C2 substitution probed geometrically through hA(2A)ARdocking was important for binding in order of hexynyl > hexenyl > hexanyl. Compound 4g was the most potent ligand acting dually as hA(2A)AR agonist and hA(3)AR antagonist, which might be useful for treatment of asthma or other inflammatory diseases.
  • Structure–activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists
    作者:Shantanu Pal、Won Jun Choi、Seung Ah Choe、Cara L. Heller、Zhan-Guo Gao、Moshe Chinn、Kenneth A. Jacobson、Xiyan Hou、Sang Kook Lee、Hea Ok Kim、Lak Shin Jeong
    DOI:10.1016/j.bmc.2009.03.034
    日期:2009.5
    On the basis of potent and selective binding affinity of truncated 4'-thioadenosine derivatives at the human A(3) adenosine receptor (AR), their bioisosteric 4'-oxo derivatives were designed and synthesized from commercially available 2,3-O-isopropylidene-D-erythrono lactone. The derivatives tested in AR binding assays were substituted at the C2 and N-6 positions. All synthesized nucleosides exhibited potent and selective binding affinity at the human A(3) AR. They were less potent than the corresponding 4'-thio analogues, but showed still selective to other subtypes. The 2-Cl series generally were better than the 2-H series in view of binding affinity and selectivity. Among compounds tested, compound 5d (X=Cl, R=3-bromobenzyl) showed the highest binding affinity (K-i = 13.0 +/- 6.9 nM) at the hA(3) AR with high selectivity (at least 88-fold) in comparison to other AR subtypes. Like the corresponding truncated 4'-thio series, compound 5d antagonized the action of an agonist to inhibit forskolin-stimulated adenylate cyclase in hA(3) AR-expressing CHO cells. Although the 4'-oxo series were less potent than the 4'-thio series, this class of human A(3) AR antagonists is also regarded as another good template for the design of A(3) AR antagonists and for further drug development. (C) 2009 Elsevier Ltd. All rights reserved.
  • GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A<sub>2A</sub> Adenosine Receptor
    作者:Anna Shiriaeva、Daejin Park、Gyudong Kim、Yoonji Lee、Xiyan Hou、Dnyandev B. Jarhad、Gibae Kim、Jinha Yu、Young Eum Hyun、Woomi Kim、Zhan-Guo Gao、Kenneth A. Jacobson、Gye Won Han、Raymond C. Stevens、Lak Shin Jeong、Sun Choi、Vadim Cherezov
    DOI:10.1021/acs.jmedchem.2c00462
    日期:2022.9.8
查看更多